BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


SEARCH JOBS








 Company News
Protalix Biotherapeutics, Inc. (PLX) Announces Oral GCD Data To Be Presented At WORLD Symposium 2014 2/12/2014 9:21:39 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Announces Successful Manufacturing Facility Evaluation By Health Canada 1/24/2014 9:01:14 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Provides Full-Year 2014 Strategic Outlook 1/13/2014 9:45:07 AM    More...
Protalix Biotherapeutics, Inc. (PLX) To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/7/2014 9:40:49 AM    More...
Protalix Biotherapeutics, Inc. (PLX) To Present At Oppenheimer's 24th Annual Healthcare Conference 12/3/2013 8:58:49 AM    More...
Protalix Biotherapeutics, Inc. (PLX) to Present at Upcoming Scientific and Medical Meetings 10/31/2013 9:53:01 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Phase I Clinical Trial Results for Oral GCD in Gaucher Disease Patients 10/14/2013 9:21:24 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Announces Closing of $69 Million Offering of Convertible Notes 9/18/2013 9:45:47 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Announces Proposed $60 Million Offering of Convertible Notes 9/12/2013 9:32:23 AM    More...
Protalix Biotherapeutics, Inc. (PLX) Discloses Three New Compounds in Development 6/21/2013 9:43:36 AM    More...
12345678910...

//-->